These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

627 related items for PubMed ID: 16263884

  • 1. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis.
    Hogan SL, Falk RJ, Chin H, Cai J, Jennette CE, Jennette JC, Nachman PH.
    Ann Intern Med; 2005 Nov 01; 143(9):621-31. PubMed ID: 16263884
    [Abstract] [Full Text] [Related]

  • 2. Summaries for patients. Relapse and treatment resistance in patients with small-vessel vasculitis.
    Ann Intern Med; 2005 Nov 01; 143(9):I22. PubMed ID: 16263880
    [No Abstract] [Full Text] [Related]

  • 3. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts.
    Pagnoux C, Hogan SL, Chin H, Jennette JC, Falk RJ, Guillevin L, Nachman PH.
    Arthritis Rheum; 2008 Sep 01; 58(9):2908-18. PubMed ID: 18759282
    [Abstract] [Full Text] [Related]

  • 4. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment.
    Sanders JS, Huitma MG, Kallenberg CG, Stegeman CA.
    Rheumatology (Oxford); 2006 Jun 01; 45(6):724-9. PubMed ID: 16399845
    [Abstract] [Full Text] [Related]

  • 5. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.
    Sanders JS, de Joode AA, DeSevaux RG, Broekroelofs J, Voskuyl AE, van Paassen P, Kallenberg CG, Tervaert JW, Stegeman CA.
    Nephrol Dial Transplant; 2016 Sep 01; 31(9):1453-9. PubMed ID: 27242368
    [Abstract] [Full Text] [Related]

  • 6. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis.
    Slot MC, Tervaert JW, Boomsma MM, Stegeman CA.
    Arthritis Rheum; 2004 Apr 15; 51(2):269-73. PubMed ID: 15077271
    [Abstract] [Full Text] [Related]

  • 7. Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3.
    Fussner LA, Hummel AM, Schroeder DR, Silva F, Cartin-Ceba R, Snyder MR, Hoffman GS, Kallenberg CG, Langford CA, Merkel PA, Monach PA, Seo P, Spiera RF, William St Clair E, Tchao NK, Stone JH, Specks U, Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group.
    Arthritis Rheumatol; 2016 Jul 15; 68(7):1700-10. PubMed ID: 26882078
    [Abstract] [Full Text] [Related]

  • 8. Increase of Antimyeloperoxidase Antineutrophil Cytoplasmic Antibody (ANCA) in Patients with Renal ANCA-associated Vasculitis: Association with Risk to Relapse.
    Yamaguchi M, Ando M, Kato S, Katsuno T, Kato N, Kosugi T, Sato W, Tsuboi N, Yasuda Y, Mizuno M, Ito Y, Matsuo S, Maruyama S.
    J Rheumatol; 2015 Oct 15; 42(10):1853-60. PubMed ID: 26373560
    [Abstract] [Full Text] [Related]

  • 9. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement.
    Hu W, Liu C, Xie H, Chen H, Liu Z, Li L.
    Nephrol Dial Transplant; 2008 Apr 15; 23(4):1307-12. PubMed ID: 18065810
    [Abstract] [Full Text] [Related]

  • 10. Factors influencing patient survival and renal function outcome in pulmonary-renal syndrome associated with ANCA (+) vasculitis: a single-center experience.
    Stangou M, Asimaki A, Bamichas G, Christidou F, Zoumbaridis N, Natse T, Galanis N, Christaki P, Patakas D, Sombolos K.
    J Nephrol; 2005 Apr 15; 18(1):35-44. PubMed ID: 15772921
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
    Jayne D, Blockmans D, Luqmani R, Moiseev S, Ji B, Green Y, Hall L, Roth D, Henderson RB, Merkel PA, BREVAS Study Collaborators.
    Arthritis Rheumatol; 2019 Jun 15; 71(6):952-963. PubMed ID: 30666823
    [Abstract] [Full Text] [Related]

  • 12. Clinical and pathological manifestations of patients with antineutrophil cytoplasmic autoantibodies directed against proteinase 3 or myeloperoxidase.
    Zhang X, Dong Y, Zeng X, Li Y, Tang F.
    Chin Med Sci J; 2002 Mar 15; 17(1):32-5. PubMed ID: 12894882
    [Abstract] [Full Text] [Related]

  • 13. Plasma levels of soluble interleukin 2 receptor, soluble CD30, interleukin 10 and B cell activator of the tumour necrosis factor family during follow-up in vasculitis associated with proteinase 3-antineutrophil cytoplasmic antibodies: associations with disease activity and relapse.
    Sanders JS, Huitma MG, Kallenberg CG, Stegeman CA.
    Ann Rheum Dis; 2006 Nov 15; 65(11):1484-9. PubMed ID: 16504995
    [Abstract] [Full Text] [Related]

  • 14. ANCA-associated vasculitis: diagnostic and therapeutic strategy.
    Ozaki S.
    Allergol Int; 2007 Jun 15; 56(2):87-96. PubMed ID: 17460438
    [Abstract] [Full Text] [Related]

  • 15. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.
    De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, Gross WL, Luqmani R, Jayne DR.
    Arthritis Rheum; 2005 Aug 15; 52(8):2461-9. PubMed ID: 16052573
    [Abstract] [Full Text] [Related]

  • 16. Predictors of treatment resistance and relapse in Chinese patients with antineutrophil cytoplasmic antibody-associated disease.
    Cao Y, Tian Z, Li W, Ma L, Yu Y, Ren W.
    J Rheumatol; 2014 May 15; 41(5):916-22. PubMed ID: 24634200
    [Abstract] [Full Text] [Related]

  • 17. Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive Granulomatosis With Polyangiitis (Wegener's) Is a Clinically Distinct Subset of ANCA-Associated Vasculitis: A Retrospective Analysis of 315 Patients From a German Vasculitis Referral Center.
    Schirmer JH, Wright MN, Herrmann K, Laudien M, Nölle B, Reinhold-Keller E, Bremer JP, Moosig F, Holle JU.
    Arthritis Rheumatol; 2016 Dec 15; 68(12):2953-2963. PubMed ID: 27333332
    [Abstract] [Full Text] [Related]

  • 18. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.
    Karras A, Pagnoux C, Haubitz M, Groot K, Puechal X, Tervaert JWC, Segelmark M, Guillevin L, Jayne D, European Vasculitis Society.
    Ann Rheum Dis; 2017 Oct 15; 76(10):1662-1668. PubMed ID: 28546260
    [Abstract] [Full Text] [Related]

  • 19. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis.
    Finkielman JD, Merkel PA, Schroeder D, Hoffman GS, Spiera R, St Clair EW, Davis JC, McCune WJ, Lears AK, Ytterberg SR, Hummel AM, Viss MA, Peikert T, Stone JH, Specks U, WGET Research Group.
    Ann Intern Med; 2007 Nov 06; 147(9):611-9. PubMed ID: 17975183
    [Abstract] [Full Text] [Related]

  • 20. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.
    de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, Luqmani R, Pusey CD, Rasmussen N, Sinico RA, Tesar V, Vanhille P, Westman K, Savage CO, EUVAS (European Vasculitis Study Group).
    Ann Intern Med; 2009 May 19; 150(10):670-80. PubMed ID: 19451574
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.